Cardiotoxicity in chemotherapeutic agents
This Letter to the Editor aims to comment on the review by Duplyakov DV et al. published in this Journal, didactically discussing the cardiotoxicity in chemotherapy under the pathophysiological points of view as well as daily practical aspects. The growth of the oldest age groups of patients and the...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Limited liability company «Science and Innovations» (Saratov)
2021-03-01
|
| Series: | Russian Open Medical Journal |
| Subjects: | |
| Online Access: | https://romj.org/node/363 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850133141574909952 |
|---|---|
| author | Vitorino Modesto dos Santos Lister Arruda Modesto dos Santos |
| author_facet | Vitorino Modesto dos Santos Lister Arruda Modesto dos Santos |
| author_sort | Vitorino Modesto dos Santos |
| collection | DOAJ |
| description | This Letter to the Editor aims to comment on the review by Duplyakov DV et al. published in this Journal, didactically discussing the cardiotoxicity in chemotherapy under the pathophysiological points of view as well as daily practical aspects. The growth of the oldest age groups of patients and the increased number of malignant entities undergoing chemotherapy enhances the significance of the cited work. One of the key points is the emphasis on the possibility of a known risk of cardiovascular damage due to chemotherapy surpass that of the malignancy under treatment. An additional short comment is about reversible cardiotoxicity in a 54-year-old Brazilian woman with breast cancer treated by trastuzumab. The herein commented articles can contribute to better understanding of mechanisms in cardiotoxicity related to chemotherapy, and to reduce the under diagnosis. |
| format | Article |
| id | doaj-art-0e69974ec9ed4819bb64beaf0bfc3892 |
| institution | OA Journals |
| issn | 2304-3415 |
| language | English |
| publishDate | 2021-03-01 |
| publisher | Limited liability company «Science and Innovations» (Saratov) |
| record_format | Article |
| series | Russian Open Medical Journal |
| spelling | doaj-art-0e69974ec9ed4819bb64beaf0bfc38922025-08-20T02:32:03ZengLimited liability company «Science and Innovations» (Saratov)Russian Open Medical Journal2304-34152021-03-01101e010610.15275/rusomj.2021.0106Cardiotoxicity in chemotherapeutic agentsVitorino Modesto dos SantosLister Arruda Modesto dos SantosThis Letter to the Editor aims to comment on the review by Duplyakov DV et al. published in this Journal, didactically discussing the cardiotoxicity in chemotherapy under the pathophysiological points of view as well as daily practical aspects. The growth of the oldest age groups of patients and the increased number of malignant entities undergoing chemotherapy enhances the significance of the cited work. One of the key points is the emphasis on the possibility of a known risk of cardiovascular damage due to chemotherapy surpass that of the malignancy under treatment. An additional short comment is about reversible cardiotoxicity in a 54-year-old Brazilian woman with breast cancer treated by trastuzumab. The herein commented articles can contribute to better understanding of mechanisms in cardiotoxicity related to chemotherapy, and to reduce the under diagnosis.https://romj.org/node/363cardiotoxicitydoxorubicintrastuzumabbevacizumabcyclophosphamide |
| spellingShingle | Vitorino Modesto dos Santos Lister Arruda Modesto dos Santos Cardiotoxicity in chemotherapeutic agents Russian Open Medical Journal cardiotoxicity doxorubicin trastuzumab bevacizumab cyclophosphamide |
| title | Cardiotoxicity in chemotherapeutic agents |
| title_full | Cardiotoxicity in chemotherapeutic agents |
| title_fullStr | Cardiotoxicity in chemotherapeutic agents |
| title_full_unstemmed | Cardiotoxicity in chemotherapeutic agents |
| title_short | Cardiotoxicity in chemotherapeutic agents |
| title_sort | cardiotoxicity in chemotherapeutic agents |
| topic | cardiotoxicity doxorubicin trastuzumab bevacizumab cyclophosphamide |
| url | https://romj.org/node/363 |
| work_keys_str_mv | AT vitorinomodestodossantos cardiotoxicityinchemotherapeuticagents AT listerarrudamodestodossantos cardiotoxicityinchemotherapeuticagents |